X4 Pharmaceuticals (XFOR) Projected to Announce Quarterly Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR) is projected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.19) per share and revenue of $2.42 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The company had revenue of $2.71 million during the quarter, compared to analysts’ expectations of $3.20 million. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

X4 Pharmaceuticals Stock Performance

Shares of X4 Pharmaceuticals stock opened at $4.09 on Tuesday. The stock’s fifty day moving average is $4.01 and its two-hundred day moving average is $3.93. The company has a market capitalization of $385.77 million, a PE ratio of -0.90 and a beta of 0.37. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.83.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the transaction, the chief financial officer directly owned 167,750 shares in the company, valued at $714,615. This trade represents a 4.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.13% of the stock is owned by insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC lifted its holdings in X4 Pharmaceuticals by 227.0% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock worth $31,870,000 after buying an additional 5,530,866 shares during the period. Kalehua Capital Management LLC purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $14,891,000. Braidwell LP purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $13,476,000. Nantahala Capital Management LLC bought a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth $7,621,000. Finally, Siren L.L.C. bought a new position in shares of X4 Pharmaceuticals in the 4th quarter worth $6,000,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

XFOR has been the subject of a number of recent analyst reports. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, X4 Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $9.70.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.